30 September 2022
Towards the elimination of COPD
A comprehensive Lancet Commission publication, co-authored by research group leader Prof. Daiana Stolz, presents core strategies for preventing chronic obstructive pulmonary disease and combating it worldwide.
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide according to the World Health Organization (WHO). Morbidity and mortality due to chronic respiratory disease continues to increase. The experts judgment is that current management of the disease has failed. The aim of the Lancet Commission on COPD, led by Prof. Daiana Stolz, is to set a new course for the management and elimination of COPD.
The commission proposes six core strategies to achieve this ambitious goal: (1) developing a broader understanding of the multiple and interacting risk factors for COPD, (2) classifying the disease into different types based on underlying causative mechanisms, including genetic factors, early life events, respiratory infections, and tobacco use and other environmental influences, (3) establishing a more comprehensive COPD diagnosis that allows detection of a mild form of the disease before irreversible pathologic changes have occurred, (4) developing personalised prevention and treatment strategies for both stable disease and exacerbations based on a holistic assessment of COPD pathophysiology, symptoms, and patient needs, abilities, and preferences; (5) investing in the development of curative and regenerative therapies that go beyond largely symptomatic treatment options; and (6) using public health prevention strategies for smoking bans and clean air.
Towards the elimination of chronic obstructive pulmonary disease: a LancetCommission
Stolz D, Mkorombindo T, Schumann DM, Agusti A, Ash SY, Bafadhel M, Bai C, Chalmers JD, Criner GJ, Dharmage SC, Franssen FME, Frey U, Han M, Hansel NN, Hawkins NM, Kalhan R, Konigshoff M, Ko FW, Parekh TM, Powell P, Rutten-van Mölken M, Simpson J, Sin DD, Song Y, Suki B, Troosters T, Washko GR, Welte T, Dransfield MT.
Lancet. 2022 Sep 17; 400(10356):921-972.
doi: 10.1016/S0140-6736(22)01273-9. Epub 2022 Sep 5. PMID: 36075255.
"My desire is to make a difference that improves understanding of the disease and, more importantly, patient care. When I conduct a study, I want to make sure that at the end the results have an impact on the patient. That, to me, is the reason to do research."
From The Lancet Perspectives: Daiana Stolz: transforming the agenda for lung health